Cosentyx 300 mg — Blue Cross Blue Shield of Kansas

Initial criteria

• Diagnosis of moderate to severe plaque psoriasis with or without coexistent active psoriatic arthritis AND requested dose is 300 mg every 4 weeks OR
• Diagnosis of hidradenitis suppurativa AND (requested dose is 300 mg every 4 weeks OR requested dose is 300 mg every 2 weeks AND patient has tried and had inadequate response to Cosentyx 300 mg every 4 weeks after ≥ 3 months) OR
• Diagnosis of active psoriatic arthritis or active ankylosing spondylitis AND (requested dose is 300 mg every 4 weeks AND patient has tried and had inadequate response to Cosentyx 150 mg every 4 weeks after ≥ 3 months)

Approval duration

12 months